Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiridon, C. I.
Right arrow Articles by Vitetta, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiridon, C. I.
Right arrow Articles by Vitetta, E. S.
Clinical Cancer Research Vol. 8, 1720-1730, June 2002
© 2002 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo1

Camelia I. Spiridon, Maria-Ana Ghetie, Jonathan Uhr, Radu Marches, Jia-Ling Li, Guo-Liang Shen and Ellen S. Vitetta2

Cancer Immunobiology Center, U. T. Southwestern Medical School, Dallas, Texas 75390-8576

Her-2 (p185erbB-2) is a transmembrane tyrosine kinase receptor, which is encoded by the Her-2/neu proto-oncogene. Her-2 is overexpressed on 30% of highly malignant breast cancers. Monoclonal antibodies (MAbs) against Her-2 inhibit the growth of Her-2-overexpressing tumor cells and this occurs by a variety of mechanisms. One such MAb, Herceptin (Trastuzumab), has been approved for human use. We have generated a panel of murine anti-Her-2 MAbs against nine different epitopes on the extracellular domain of Her-2 and have evaluated the antitumor activity of three of these MAbs alone and in combination, both in vitro and in vivo. We found that MAbs (against different epitopes) make a highly effective mixture, which was more effective than the individual MAbs in treating s.c. tumor nodules of BT474 cells in SCID mice. In vitro, the MAb mixture was also more effective than the single MAbs in inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, inhibiting cell growth and inducing apoptosis, and inhibiting the secretion of vascular endothelial growth factor. Taken together, these activities might explain the superior performance of the MAb mixture in vivo.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. Dechant, W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Bueren, W. K. Bleeker, P. W.H.I. Parren, J. G.J. van de Winkel, et al.
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
Cancer Res., July 1, 2008; 68(13): 4998 - 5003.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Chakravarty, R. Marches, N. S. Zimmerman, A. D.-E. Swafford, P. Bajaj, I. H. Musselman, P. Pantano, R. K. Draper, and E. S. Vitetta
Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes
PNAS, June 24, 2008; 105(25): 8697 - 8702.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. C. Portera, J. M. Walshe, D. R. Rosing, N. Denduluri, A. W. Berman, U. Vatas, M. Velarde, C. K. Chow, S. M. Steinberg, D. Nguyen, et al.
Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2710 - 2716.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Katsumi, Y. Kuwahara, S. Tamura, K. Kikuchi, O. Otabe, K. Tsuchiya, T. Iehara, H. Kuroda, H. Hosoi, and T. Sugimoto
Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
Clin. Cancer Res., February 15, 2008; 14(4): 1192 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco
In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab
Cancer Res., November 1, 2007; 67(21): 10556 - 10563.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Barok, J. Isola, Z. Palyi-Krekk, P. Nagy, I. Juhasz, G. Vereb, P. Kauraniemi, A. Kapanen, M. Tanner, G. Vereb, et al.
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mol. Cancer Ther., July 1, 2007; 6(7): 2065 - 2072.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Macor, D. Mezzanzanica, C. Cossetti, P. Alberti, M. Figini, S. Canevari, and F. Tedesco
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Cancer Res., April 1, 2006; 66(7): 3876 - 3883.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel
Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. De Lorenzo, R. Cozzolino, A. Carpentieri, P. Pucci, P. Laccetti, and G. D'Alessio
Biological properties of a human compact anti-ErbB2 antibody
Carcinogenesis, November 1, 2005; 26(11): 1890 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Petronzelli, A. Pelliccia, A. M. Anastasi, V. D'Alessio, C. Albertoni, A. Rosi, B. Leoni, C. De Angelis, G. Paganelli, G. Palombo, et al.
Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies
Clin. Cancer Res., October 1, 2005; 11(19): 7137s - 7145s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. D. Savellano, B. W. Pogue, P. J. Hoopes, E. S. Vitetta, and K. D. Paulsen
Multiepitope HER2 Targeting Enhances Photoimmunotherapy of HER2-Overexpressing Cancer Cells with Pyropheophorbide-a Immunoconjugates
Cancer Res., July 15, 2005; 65(14): 6371 - 6379.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Nagata, T. Ise, M. Onda, K. Nakamura, M. Ho, A. Raubitschek, and I. H. Pastan
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy
PNAS, May 31, 2005; 102(22): 7946 - 7951.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. D. Savellano and T. Hasan
Photochemical Targeting of Epidermal Growth Factor Receptor: A Mechanistic Study
Clin. Cancer Res., February 15, 2005; 11(4): 1658 - 1668.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. M. Friedman, A. Rinon, B. Schechter, L. Lyass, S. Lavi, S. S. Bacus, M. Sela, and Y. Yarden
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
PNAS, February 8, 2005; 102(6): 1915 - 1920.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Hong, J. Yan, J. T. Baran, D. J. Allendorf, R. D. Hansen, G. R. Ostroff, P. X. Xing, N.-K. V. Cheung, and G. D. Ross
Mechanism by Which Orally Administered {beta}-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models
J. Immunol., July 15, 2004; 173(2): 797 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
A. J. Olszewski and M. L. Grossbard
Empowering Targeted Therapy: Lessons from Rituximab
Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. I. Spiridon, S. Guinn, and E. S. Vitetta
A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab')2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies
Clin. Cancer Res., May 15, 2004; 10(10): 3542 - 3551.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Nahta, M.-C. Hung, and F. J. Esteva
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells
Cancer Res., April 1, 2004; 64(7): 2343 - 2346.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Hong, R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross
{beta}-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells
Cancer Res., December 15, 2003; 63(24): 9023 - 9031.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. E. Wolpoe, E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice
J. Immunol., August 15, 2003; 171(4): 2161 - 2169.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.